Advertisement
UK markets close in 3 hours 41 minutes

  • FTSE 100

    7,862.39
    +14.40 (+0.18%)
     

  • FTSE 250

    19,401.29
    +61.15 (+0.32%)
     

  • AIM

    744.34
    +1.22 (+0.16%)
     

  • GBP/EUR

    1.1683
    +0.0016 (+0.13%)
     

  • GBP/USD

    1.2471
    +0.0014 (+0.12%)
     

  • Bitcoin GBP

    50,226.24
    -286.41 (-0.57%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • CRUDE OIL

    82.27
    -0.42 (-0.51%)
     

  • GOLD FUTURES

    2,397.20
    +8.80 (+0.37%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     

  • DAX

    17,769.02
    -1.00 (-0.01%)
     

  • CAC 40

    8,008.40
    +26.89 (+0.34%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference

Silence Therapeutics plc
·2-min read

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference

5 January 2022

LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a fireside chat during the H.C. Wainwright BioConnect Virtual Conference on January 10 – 13, 2022.

The on-demand presentation will be available beginning on Monday, January 10 at 7:00am ET / 12:00pm GMT and can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.

Enquiries:

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com





US Media Relations

MKC Strategies

Mary Conway

mconway@mkcstrategies.com



Tel: +1 (646) 637-3208









Tel: +1 (516) 606-6545

European Media Relations

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.